TITLE

Rituximab and alemtuzumab produced 100% response rate in autoimmune cytopenias

AUTHOR(S)
Cona, Christen; Harris, Jason; Southall, Jennifer
PUB. DATE
October 2010
SOURCE
Hem/Onc Today;10/25/2010, Vol. 11 Issue 20, p23
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses research being done on the effectiveness of combining rituximab and alemtuzumab for the treatment of patients with steroid-refractory autoimmune cytopenias, which references a study by D. Gómez-Almaguer and colleagues in a 2010 issue of the journal "Blood."
ACCESSION #
54422849

 

Related Articles

  • Rituximab.  // Reactions Weekly;1/30/2016, Vol. 1586 Issue 1, p257 

    An abstract of the article "Hypersensitivity to rituximab: A rapid and simplified desensitization protocol for patients with ancaassociated vasculitis and other autoimmune disorders" by A. Berti and others is presented.

  • Association of the FCGR3A-158F/V Gene Polymorphism with the Response to Rituximab Treatment in Spanish Systemic Autoimmune Disease Patients. Robledo, Gema; Márquez, Ana; Dávila-Fajardo, Cristina Lucía; Ortego-Centeno, Norberto; Rubio, José Luis Callejas; Garrido, Enrique de Ramón; Sánchez-Román, Julio; García-Hernández, Francisco J.; Ríos-Fernández, Raquel; González-Escribano, Maria Francisca; García, Maria Teresa Camps; Palma, Maria Jesús Castillo; Ayala, Maria del Mar; Martín, Javier // DNA & Cell Biology;Dec2012, Vol. 31 Issue 12, p1671 

    Rituximab is being used as treatment for systemic autoimmune diseases. The objective of this study was to determine whether the genetic variant in the Fc gamma-receptor III a ( FCGR3A) gene, 158F/V, contributes to the observed variation in response to rituximab in patients with systemic...

  • Good Cells Gone Bad. Mann, Denise; Siegfried, Donna Rae // Arthritis Today;Sep/Oct2004, Vol. 18 Issue 5, p34 

    Presents information on several experimental drugs for treating autoimmune diseases. Causes of muscle inflammation; Effect of the drug rituximab on B cells; Background on the Lymphostat-B drug. INSET: IS IT OK TO USE THE WORD "CURE"?.

  • Rituximab-based therapy and long-term control of autoimmune autonomic ganglionopathy. Gupta, Arjun; Harris, Samar; Vernino, Steven; Naina, Harris // Clinical Autonomic Research;Aug2015, Vol. 25 Issue 4, p255 

    We present a patient with autoimmune autonomic ganglionopathy (AAG) who had persistently positive ganglionic nicotinic acetylcholine receptor antibody levels despite immunosuppressive therapy. Rituximab-based therapy for an incidental lymphoma was associated with prolonged symptomatic and...

  • Current Treatment of Autoimmune Blistering Diseases. Kasperkiewicz, Michael; Schmidt, Enno // Current Drug Discovery Technologies;Dec2009, Vol. 6 Issue 4, p270 

    Autoimmune bullous diseases are a heterogeneous group of disorders that can be subdivided according to the level of split formation in the intraepidermal blistering pemphigus diseases and subepidermal bullous disorders, latter including pemphigoid diseases, epidermolysis bullosa acquisita, and...

  • Rituximab Therapy and Autoimmune Disease. Yadav, Asha Ram; Deo, Nirmala // Current Immunology Reviews;Feb2012, Vol. 8 Issue 1, p94 

    In recent years, advances in our understanding of the regulation of the immune system have enabled the identification of cellular and molecular targets that could affect the pathogenesis of many autoimmune diseases. B-cells play pivotal role in autoantigen presentation and in autoantibody...

  • Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Ojeda-Uribe, Mario; Afif, Naji; Dahan, Etienne; Sparsa, Laetitia; Haby, Celine; Sibilia, Jean; Ternant, David; Ardizzone, Marc // Clinical Rheumatology;May2013, Vol. 32 Issue 5, p695 

    The use of biological therapies for treating autoimmune diseases is increasing. These therapies are sometimes administered to pregnant women as part of a planned therapeutic regimen or to women with unexpected or unplanned pregnancies. The safety of biological therapies in this setting is a...

  • Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Jónsdóttir, Thórunn; Gunnarsson, Iva; Mourão, Ana Filipa; Lu, Tim Y.; Van Vollenhoven, Ronald F.; Isenberg, David // Rheumatology;Aug2010, Vol. 49 Issue 8, p1502 

    Objective. To compare the clinical results after treatment with B-cell depleting therapy in patients with membranous (WHO Class V) vs proliferative (WHO Class III or IV) lupus nephritis (LN).

  • Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Hart, Phil A.; Topazian, Mark D.; Witzig, Thomas E.; Clain, Jonathan E.; Gleeson, Ferga C.; Klebig, Robin R.; Levy, Michael J.; Pearson, Randall K.; Petersen, Bret T.; Smyrk, Thomas C.; Sugumar, Aravind; Takahashi, Naoki; Vege, Santhi S.; Chari, Suresh T. // Gut;Nov2013, Vol. 62 Issue 11, p1607 

    Background: There is a paucity of data on long-term management of type 1 autoimmune pancreatitis (AIP), a relapsing steroid-responsive disorder. Objective: We describe our experience with treatment of relapses and maintenance of remission using steroidsparing immunomodulators (IMs) and induction...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics